M ost previous studies have evaluated risk factors for cardiovascular death and the impact of therapeutic interventions in terms of either all-cause mortality or total cardiac mortality. Although death in patients with ischemic cardiomyopathy is usually because of underlying cardiac disease, the cause-specific mechanism is almost equally split between sudden cardiac arrest (SCA) from arrhythmic events and nonsudden cardiac death (NSCD) because of pump failure. Implantable cardiac defibrillators (ICDs) can effectively terminate lethal ventricular arrhythmias, and their prophylactic use has been shown to improve survival.
1,2 Nevertheless, they do nothing to mitigate NSCD. As a result, their overall clinical benefit may become limited in circumstances where the competing risk from NSCD and noncardiac death is high. For example, advanced heart failure symptoms predict a high likelihood of death from pump failure, and because of this, patients with New York Heart Association function class IV heart failure symptoms are generally not considered candidates for a primary-prevention ICD. Despite intense investigation, identification of patients at high risk of arrhythmic death is currently based primarily on a depressed left ventricular (LV) ejection fraction (EF). Unfortunately, EF does not accurately distinguish cause-specific mortality because the risk of arrhythmic death and death from heart failure both increase as EF declines.
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Targeting of ICD therapy to patients at highest risk could be significantly advanced by identifying factors that predict Background-Previous studies have identified multiple risk factors that are associated with total cardiac mortality.
Nevertheless, identifying specific factors that distinguish patients at risk of arrhythmic death versus heart failure could better target patients likely to benefit from implantable cardiac defibrillators, which have no impact on nonsudden cardiac death. Methods and Results-We performed a pilot competing risks analysis of the National Institutes of Health-sponsored PAREPET trial (Prediction of Arrhythmic Events with Positron Emission Tomography). Death from cardiac causes was ascertained in subjects with ischemic cardiomyopathy (n=204) eligible for an implantable cardiac defibrillator for the primary prevention of sudden cardiac arrest after baseline clinical evaluation and imaging at enrollment (positron emission tomography and 2-dimensional echo). Mean age was 67±11 years with an ejection fraction of 27±9%, and 90% were men. During 4.1 years of follow-up, there were 33 sudden cardiac arrests (arrhythmic death or implantable cardiac defibrillator discharge for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36 nonsudden cardiac deaths. Sudden cardiac arrest was correlated with a greater volume of denervated myocardium (defect of the positron emission tomography norepinephrine analog cause-specific mortality from SCA. [3] [4] [5] [6] [7] [8] The few studies that have considered SCA have usually ignored the fact that NSCD is an equally frequent competing end point. The ability to risk stratify patients in terms of cause-specific mortality would advance our ability to identify those most likely to benefit from an ICD. 8, 9 In addition, predicting an increased risk of NSCD could be used to identify patients who might benefit from alternate or aggressive up-titration of medical therapy for heart failure or even a patient cohort at such high risk of NSCD that ICD therapy should perhaps be withheld. 5, 10, 11 Toward this end, we determined whether specific risk factors could be identified that were associated with SCA versus NSCD using a competing risks analysis of the PAREPET trial (Prediction of Arrhythmic Events with Positron Emission Tomography). The results identify independent risk factors that are associated with cause-specific cardiac mortality in a cohort with ischemic cardiomyopathy eligible for a primaryprevention ICD.
Methods

Study Population
The National Institutes of Health-sponsored PAREPET trial (Data Supplement) 12, 13 enrolled 204 subjects with ischemic cardiomyopathy who were eligible to receive an ICD for the primary prevention of SCA.
12,13 ICD implantation was refused by 29 subjects (14%), with no significant differences in any study variable between those with and without an ICD (Data Supplement). All subjects gave informed consent, and the study was approved by the University at Buffalo and Veterans Affairs Western New York Healthcare System Institutional Review Boards.
Positron Emission Tomography
PET imaging was performed as described previously. 12, 13 Briefly, myocardial sympathetic innervation was assessed with 11 C-metahydroxyephedrine, 13 N-ammonia was used to measure perfusion, and 18 F-2-deoxyglucose during a hyperinsulinemic-euglycemic clamp was used to confirm metabolic viability. 12, 13 PET images were analyzed with FlowQuant software (University of Ottawa Heart Institute).
14 Tracers were quantified in each of 496 myocardial sectors relative to the peak tracer activity determined from the highest 5% of sectors.
12,14 11 C-meta-hydroxyephedrine uptake <75% of the peak activity defined denervated myocardium. 12, 13 Sectors with 13 N-ammonia or 18 F-2-deoxyglucose ≥80% of the peak activity were considered normal. Infarcted and hibernating myocardium were quantified from a mismatch analysis between 13 N-ammonia and 18 F-2-deoxyglucose. 13, 14 All defects were quantified as the integrated reduction in each sector with reduced uptake and expressed as percentage of the LV.
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Echocardiography and Electrocardiography
Transthoracic echocardiography was performed with a 2.25 MHz phased-array transducer with harmonic imaging (SONOS 7500; Philips Medical, Inc). 12 Chamber volumes and LVEF were quantified as recommended by the American Society of Echocardiography. A resting supine ECG was obtained at 1000 Hz (H12+ recorders, V3.12; Mortara Instruments).
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Clinical End Points
The primary end point was SCA (including ICD equivalent), with a secondary end point of total cardiac mortality (Data Supplement). 12, 13 Because ICD therapy overestimates the frequency of SCA in control subjects, the ICD equivalent for SCA was conservatively defined as ICD discharge for fast ventricular tachycardia (>240 bpm) or ventricular fibrillation. 12, 13 The secondary end point of total cardiac mortality included SCA and NSCD. This was blindly adjudicated by 3 boardcertified cardiologists.
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Statistical Analyses
All values are mean±SD. Differences between groups were compared using unpaired t tests for continuous data and the χ 2 test for categorical values (Microsoft Excel). Variables were tested for their association with total cardiac mortality, SCA, and NSCD (Data Supplement). 13 Multivariable analyses for these individual end points were performed with backward selection (SAS; Cary, NC). Statistical significance was defined as a 2-tailed P≤0.05. The time to end points was analyzed using the Kaplan-Meier method, and the difference between groups was assessed with the log-rank statistic.
A competing risks analysis was performed to simultaneously assess factors associated with SCA and NSCD (Data Supplement). The variables that resulted from the multivariable analyses of the individual end points (total cardiac mortality, SCA, or NSCD) were included in the competing risks analysis. The competing risks analysis was performed using the cmprsk package 16 within the R statistical software, 17 which fits proportional subdistribution hazard regression models. 18 Backward selection was used to find all statistically significant variables for both SCA and NSCD. Follow-up analyses of the significant variables from the competing risks analysis used modelbased standardized risk estimates.
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Results Table 1 summarizes the key variables. Almost all subjects received antiplatelet therapy or warfarin (99%), β-blockers (96%), and angiotensin inhibition therapy (angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist, 90%). During a median follow-up of 4.1±1.9 years, there were 69 cardiac deaths (34%), of which 33 (16%; ≈4.1% per year) were SCA and 36 (18%; ≈4.3% per year) were NSCD ( Figure 1 ). Of the 33 SCA events, 11 were ICD equivalents. Variables associated with time to the various end points (total cardiac mortality, SCA, and NSCD) are summarized in Table 2 and Table II in the Data Supplement. Of the PET variables, only denervated myocardium was associated with total cardiac mortality, and denervated and viable denervated myocardium (mismatch between 18 F-2-deoxyglucose and 11 C-meta-hydroxyephedrine uptake) were associated with SCA.
Individual multivariable analyses were performed to determine the independent factors for time to total cardiac mortality, SCA, and NSCD (Table 3 ). The variables that were independently associated with total cardiac mortality included LV end-diastolic volume index (LVEDVI), B-type natriuretic peptide (BNP), creatinine, and angiotensin inhibition therapy. Independent variables for SCA also included LVEDVI, creatinine, and angiotensin inhibition therapy, as well as denervated myocardium. Four different variables correlated with NSCD: age, heart rate, left atrial volume index, and LVEF. The 9 variables that were identified using these analyses (Table 3) were included in the competing risks model (details below). Cumulative distribution functions comparing total and causespecific mortality for each of these variables are illustrated in Figures 2 through 4 .
Competing Risks Model
In the competing risks analysis, LVEF was not associated with NSCD (P=0.21) or SCA (P=0.82). The remaining 8 variables were significantly associated with SCA or NSCD (Table 4) . After adjustment for competing risks, SCA was associated with a greater volume of denervated myocardium, elevated BNP, no angiotensin inhibition therapy, and larger LVEDVI. NSCD was associated with elevated LVEDVI, higher resting heart rate, larger left atrial volume index, elevated creatinine, and older age. If denervated myocardium was excluded from the competing risks model, there were only minor changes (Table 5) . Figures 5 and 6 illustrate the effect of each of these variables on the probability of SCA and NSCD using modelbased standardized risk estimates while controlling for the other variables. 19 For the continuous variables, significant relationships with individual end points are reflected by changes in risk across the range of data, whereas nonsignificant relationships produce more horizontal curves. Importantly, when assessed as continuous variables, the 5-year event rate for SCA risk progressively rose with increases in the amount of denervated myocardium, LVEDVI, and BNP, whereas NSCD declined. In contrast, the 5-year NSCD event rate progressively rose with increases in resting heart rate, creatinine, left atrial volume index, and age, whereas SCA declined or remained unchanged.
Discussion
Patients with ischemic cardiomyopathy who are eligible for an ICD for the primary prevention of SCA constitute a cohort at high risk of cardiac mortality (34% at a median follow-up of 4.1 years in the present study). Multivariable analysis demonstrates independent variables associated with an increased risk of total cardiac mortality. These included LVEDVI, BNP, creatinine, and the lack of angiotensin inhibition therapy. Although evaluating the risk of cardiac mortality provides prognostic information, cost-effective decision making with regard to ICD therapy for primary prevention requires approaches to discriminate patients with high risk of SCA from those more likely to succumb to heart failure and pump dysfunction. 8, 20 In this regard, our pilot competing risks analysis identifies a set of variables that are independently associated with SCA versus NSCD in this high-risk cohort with ischemic cardiomyopathy. If prospectively validated in a larger population, this could provide an approach to improve the targeting of ICD therapy to patients at the greatest risk of arrhythmic death.
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Variables Associated With Sudden Versus NSCD
Relatively few studies have evaluated cause-specific mortality and most, including the primary analysis of the PAREPET trial, 13 focused on SCA versus death from all other causes. The present study extends our original report by providing novel information from a competing risks analysis. The competing risks methodology allows for the simultaneous assessment of the mutually exclusive components of cardiac mortality, namely SCA and NSCD. With regard to SCA, 3 of the variables remained the same as in the original multivariable analysis of SCA alone. 13 These included greater extent of denervated myocardium, larger LVEDVI, and lack of angiotensin inhibition therapy. The competing risks analysis replaced an elevated creatinine with an elevated BNP. This change is consistent with a previous study that evaluated clinical, hemodynamic, and neurohormonal factors in patients with heart failure and found that BNP was the only independent variable associated with SCA. 3 The factors we identified suggest that SCA risk is not only influenced by potential alterations in ventricular repolarization (because of regional sympathetic denervation) 13 but also by ventricular remodeling (as reflected by elevated LVEDVI and prevented by angiotensin inhibition therapy) and chronic elevations in LV end-diastolic pressure (BNP). These factors would also tend to promote interstitial fibrosis, which would delay ventricular impulse conduction and increase the risk of reentry. They could also lead to stretch-induced arrhythmogenesis, which has been observed in an animal model of sudden death from chronic ischemia without infarction. 21 In terms of NSCD, the competing risks analysis identified elevated resting heart rate, larger left atrial volume index, elevated creatinine, and older age in addition to larger LVEDVI. This association of older age with NSCD is consistent with previous findings. Although the incidence of both SCA and NSCD rises with age, 22 the proportion of deaths that are sudden declines, reflecting both a greater increase in NSCD and an increasing likelihood of noncardiac causes. 7, 8, 22 Although the other variables have been previously associated with total cardiac mortality, there is limited data on their utility for cause-specific cardiovascular mortality. The significant association between creatinine and NSCD in the competing risks analysis corroborates the conclusions of previous studies which have suggested that ICD therapy may be less effective among those with advanced chronic kidney disease.
5,8,23
Comparison With Previous Studies
To our knowledge, only 2 prior studies 6, 7 have performed competing risks analysis of SCA versus NSCD without the Table 2 . Competing Risks in Ischemic Cardiomyopathy confounding effects of including patients with a history of resuscitated SCA. 10, 11 In the ATLAS trial (assessment of treatment with lisinopril and survival, conducted from 1992 to 1997), both sudden and nonsudden death were associated with older age, ischemic LV dysfunction, lower EF, and elevated creatinine. In addition, SCA was correlated with nitrate therapy, prestudy angiotensin converting enzyme inhibitor therapy, lack of β-blocker therapy, and lack of antiarrhythmic therapy. Additional risk factors for NSCD included a lower systolic blood pressure, elevated resting heart rate, lower serum sodium, antiarrhythmic therapy, and lack of aspirin therapy. Although there are some similarities with the results of the present analysis, Figure 3 . Cumulative distribution functions for variables preferentially associated with sudden cardiac arrest. In addition to associations with total cardiac mortality (left graphs), denervated myocardium and angiotensin inhibition therapy were also significantly associated with sudden cardiac arrest (middle graphs). However, neither variable was associated with nonsudden cardiac death (right graphs). The event rates for the high-risk (red lines; denervated myocardium >32.8% of left ventricle (LV) and no angiotensin inhibition therapy), intermediaterisk (yellow lines), and low-risk (green lines; denervated myocardium <22.4% of LV and angiotensin inhibition therapy) tertiles are shown.
Corresponding P values for the univariate analyses using continuous variables are in Table 2 . Figure 4 . Cumulative distribution functions for variables preferentially associated with nonsudden cardiac death. Resting heart rate, age, and left atrial (LA) volume index were significantly associated with nonsudden cardiac death (right graphs). None of the variables were associated with sudden cardiac arrest (middle graphs), and only LA volume index was significantly associated with total cardiac mortality (left graphs). For all variables, the event rates for the high-risk (red lines; heart rate >69 bpm, age >74 y, LA volume index >46.3 mL/m 2 ), intermediate-risk (yellow lines), and low-risk (green lines; heart rate <60 bpm, age <61 y, LA volume index <33.7 mL/m 2 ) tertiles are shown. Corresponding P values for the univariate analyses using continuous variables are in Table 2 .
direct comparison is limited because of our inclusion of PET and echocardiographic imaging, as well as advances in contemporary medical therapy. A recent competing risk analysis of ambulatory heart failure patients did not identify any significant factors associated with SCA.
7 NSCD was correlated with older age, higher New York Heart Association functional class, and greater Charlson comorbidity index. 7 An alternative to a competing risk analysis was the application of the Seattle heart failure model, which was initially derived for total cardiac mortality, to cause-specific cardiac mortality. 4 When tested in >10 000 subjects with heart failure, the model successfully identified SCA and pump-failure death. 4 Assessment of the area under the receiver operating characteristic curves demonstrated that the model was significantly better for pump failure (assessment of the area under the receiver operating characteristic curves, 0.85; 95% confidence interval, 0.83-0.87) than SCA (assessment of the area under the receiver operating characteristic curves, 0.68; 95% confidence interval, 0.65-0.70). 4 Mortality decreased in those with lower scores, yet the cause of death was more likely to be sudden. With higher scores, pump-failure death predominated. 4 This observation was corroborated in an analysis of the Multicenter Automatic Defibrillator Implantation Trial-II database. Among a prespecified subgroup at high risk of death (blood urea nitrogen ≥50 mg/dL or creatinine ≥2.5 mg/dL), randomization to ICD therapy conferred no improvement in survival. 5 This important influence of renal function is consistent with our results, where elevated creatinine was an independent variable for NSCD but not SCA in the competing risks analysis (Table 4) . Recently, the Seattle proportional risk model, which was developed to predict the mode of death (sudden versus nonsudden, as opposed to risk), importantly showed that ICD benefit could in fact be predicted by a greater risk of sudden versus nonsudden death. 8 Although methodologic differences preclude accurate comparison, many variables (age, sex, renal function, diabetes mellitus, and digoxin use) show similar associations with SCA versus NSCD in the present study.
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PET Variables Associated With Cardiac Mortality
PAREPET was specifically designed to determine whether PET variables could improve the prediction of SCA (primary end point) 13 and total cardiac mortality (secondary end point). The volume of denervated myocardium was the only PET variable that showed an association with total cardiac mortality ( Table 1 ). As shown in Table 2 and Figure 3 , this primarily reflected the association of denervated myocardium with SCA. 13 In contrast to a previous study that used magnetic resonance imaging to quantify infarct size, 24 we found no correlation between the volume of infarcted myocardium and total cardiac mortality. This was likely because of the fact that by restricting our cohort to primary-prevention ICD candidates, coronary artery disease and heart failure were more advanced. In this regard, our results are consistent with other magnetic resonance imaging data showing that the peri-infarct zone of hyperenhancement, rather than core infarct size, is associated with mortality. 25 As we have previously discussed, the periinfarct region likely contains denervated but viable myocardium, which in addition to the infarct region defines the total volume of denervated myocardium. 13 Numerous investigations have determined an association between altered sympathetic innervation and SCA, with clinical studies showing denervation as a result of infarction, reversible ischemia, and nonischemic causes. 20 Although the mechanism(s) remains to be definitively determined, most evidence supports the development of an arrhythmogenic substrate because of inhomogeneity in sympathetic innervation as a result of partial denervation, nerve sprouting, and denervation hypersensitivity. 26 This results in regional inhomogeneity in ventricular repolarization, which is exacerbated during periods of sympathetic activation.
26,27
Limitations
To account for SCA events among subjects with an ICD, we included ICD discharges for ventricular fibrillation or fast ventricular tachycardia (>240 bpm) because the frequency of these arrhythmic events approximated the benefit of an ICD on survival in Multicenter Automatic Defibrillator Implantation Trial II. 28, 29 A less-restrictive threshold would obviously increase the frequency of arrhythmic events (potential SCA equivalents) and could alter the results of this analysis. Nevertheless, we have recently reported that ICD discharges for ventricular tachycardia <240 bpm seem to be associated with a different cardiac substrate (significantly less denervated myocardium) than was found among those with the present definition of SCA. 30 Secondly, ICD programming was not standardized, and the actual programming at the time of events was not recorded. This limitation may have affected the frequency of SCA equivalents. Third, adjudicated sudden death occurred in patients receiving an ICD. It is well known that ICDs do not prevent all sudden deaths from tachyarrhythmias for reasons including shock resistant ventricular tachycardia/ventricular fibrillation, postshock electromechanical dissociation, ICD under sensing, and lead malfunction, as well as causes of sudden death that are not related to ventricular tachyarrhythmias. 31 Although few device trials have adjudicated cause-specific mortality, our incidence of 10% is similar to the MUSTT trial (Multicenter Unsustained Tachycardia Trial) where the 5-year adjudicated sudden death rate using identical classification criteria was 9% in patients receiving an ICD. 32 Finally, this is a pilot study of modest size with a limited number of events; therefore, our final model is at risk of overfitting and will require prospective validation.
Clinical Implications
Although the presence of ischemic cardiomyopathy identifies a cohort that is at high risk of cardiac death, distinct subsets of clinical and imaging variables can differentially identify risk of SCA versus NSCD. Our results are consistent with previously published findings indicating that there are subgroups of primary-prevention ICD recipients in which the likelihood of NSCD without prior device therapy can significantly exceed the survival benefit of an ICD. 10 Thus, there is a significant proportion of patients at low risk of SCA when candidacy for primaryprevention ICD therapy is identified solely on the basis of EF. The primary results of the PAREPET trial corroborated this by demonstrating that the risk of SCA was low (<1% per year) in Figure 6 . Estimated event rates from the competing risks analysis for variables preferentially associated with nonsudden cardiac death. The upper graph of each pair shows the anticipated effect of each variable on sudden cardiac arrest (SCA; red lines) and nonsudden cardiac death (NSCD; blue lines) within 5 years. Resting heart rate, creatinine, left atrial (LA) volume index, and age were associated with NSCD. The probability of total cardiac mortality is also shown (black lines), although this was not directly derived from the competing risks model. The histogram associated with each variable illustrates the frequency of values in the PAREPET study (prediction of arrhythmic events with positron emission tomography), as well as the frequency of outliers (<5% of the total). For these figures, the effect of each variable is assessed individually while controlling for the other variables. The P values are derived from the competing risks analysis.
, creatinine >1.49 mg/dL, and no angiotensin inhibition therapy). 13 This group represented nearly half (44%) of our patient population. The current study extends this conclusion using a competing risk analysis, which replaced creatinine with BNP as an independent factor associated with SCA. In addition, this methodology identified independent risk factors for an increased likelihood of NSCD. If this model can be prospectively validated, it may be possible to divide patients with ischemic cardiomyopathy and an EF ≤35% into those who are likely to benefit from ICD therapy as opposed to those at high risk of NSCD, which would limit the impact of an ICD on survival.
